永安药业：2025年全年净利润同比预减56.21%—70.56%

Core Viewpoint - Yong'an Pharmaceutical is expected to report a significant decline in net profit for the year 2025, with projections indicating a decrease of 56.21% to 70.56% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is projected to be between 18.19 million and 27.05 million yuan [1] - The estimated net profit after deducting non-recurring gains and losses is expected to be between -2.88 million and -1.55 million yuan [1] Market Conditions - The company's performance is anticipated to decline sharply due to a sluggish market environment [1] - The competition in the taurine market has intensified, leading to a decrease in both the production and sales prices of the company's main product, taurine [1]